“Humility is nothing but truth, and pride is nothing but lying.” ―St. Vincent de Paul I never knew the comical extent of my pride until ALS hit me. Prior to its impact on my life, I prided myself on my independence and the manner by which I presented myself to the…
No Room for Pride when ALS Is Involved
Treatment with extracts from the Withania somnifera plant improved motor performance and delayed disease progression in mice with amyotrophic lateral sclerosis (ALS), according to researchers. The study, “Protective effects of Withania somnifera extract in SOD1G93A mouse model of amyotrophic lateral sclerosis,” was published in the journal Experimental Neurology. ALS generally develops sporadically, indicating that in…
A decline of 25 percent each year in cough peak flow, a test of cough strength and airway clearance, is a predictor of poor survival in people with amyotrophic lateral sclerosis (ALS), a small study from Japan reports. The study “Cough peak flow decline rate predicts…
Federal healthcare databases, especially Medicare, are a valuable resource in identifying cases of amyotrophic lateral sclerosis (ALS) in the U.S. population, and may help in tracking the prevalence of other neurological diseases as well, a group of researchers report. The study, “Estimation of the Prevalence of Amyotrophic Lateral Sclerosis in…
News
MicroRNA Known to Be Abundant in ALS Patients May Offer Way of Treating Disease, Study Suggests
The microRNA-218 (miR-218), produced at excessive levels by damaged or dying nerve cells, may be a therapeutic target for amyotrophic lateral sclerosis (ALS), an animal study suggests. This molecule was found to disrupt the normal function of astrocytes, star-shaped glial cells found throughout the central nervous system (brain…
A newly developed test, known as the arrows and colors cognitive test, can be used to measure cognition in amyotrophic lateral sclerosis (ALS) patients who have severe motor and verbal disabilities. A study about that assessment tool, “The Arrows and Colors Cognitive Test (ACCT): A new verbal-motor free cognitive…
“You can either celebrate what you can do, or mourn what you can’t. Every day I wake up and create a new normal. I don’t dwell on what has changed, but instead, I focus on keeping busy achieving my goals.” –Augie Nieto II, fitness pioneer Nieto and I, independently,…
An exploratory anti-cancer therapy may halt the characteristic toxic accumulation of TDP-43 in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), researchers suggest. The preclinical study, “Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization,” was published in the journal…
The first patient has been dosed in a Phase 3 clinical trial (NCT03491462) evaluating the effectiveness of Orphazyme’s investigational therapy arimoclomol in the treatment of amyotrophic lateral sclerosis (ALS). One of the disease mechanisms known to be involved in the development of ALS is protein misfolding and aggregation…
News
Physicians Asked to Help ALS Patients Die Must Evaluate Motivations, Alternatives, Case Report Says
Physicians who help amyotrophic lateral sclerosis (ALS) patients die should carefully evaluate their motivations, capacity, and care goals, while also discussing alternatives with their patient, according to researchers. An ALS patient case and commentary, “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” appeared in the…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients